Magrolimab, a humanized monoclonal antibody targeting the human cell surface antigen CD47, was an effective and tolerable treatment choice when it was combined with rituximab and chemotherapy in a phase 1b clinical study of patients with DLBCL. The gene discussed is CD47; the disease is diffuse large B-cell lymphoma.